Pre-clinical literature & target synthesis
Biomedical literature grows relentlessly, and R&D teams manually review thousands of papers, patents and lab logs to identify viable targets. The stakes are enormous: Deloitte puts the average cost of developing a drug at $2.23bn (rising to $2.67bn in its most recent analysis),51 against an industry-wide clinical failure rate of around 90%.52
Discovery teams bottlenecked on manual literature review; the risk of missing a relevant signal buried in unstructured text; slow, expensive early validation.
For patients, ultimately, slower discovery of the therapies they need.
Operating purely in the non-regulated pre-clinical research phase, the agent digests unstructured literature and lab data, maps compound correlations and assembles a structured, fully-cited dossier for the discovery team — acting as a search-and-synthesis utility that always shows its sources, so scientists verify the raw data themselves before any candidate advances.
Designed to support faster, better-organised early target validation by structuring the literature — with full citations — so scientists spend their time on judgement rather than retrieval.
For patients, the prospect of accelerated discovery; for researchers, verifiable, sourced intelligence rather than a black box.
